Where does Crinetics Pharmaceuticals's cash flow data come from?

Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$465.32M-55.9%	-$298.41M-39.1%	-$214.53M-30.9%	-$163.92M-52.3%
Depreciation and amortization	$3.89M+39.7%	$2.79M+154%	$1.1M+11.7%	$983K+6.6%
Stock-based compensation	$91.02M+31.2%	$69.39M+69.5%	$40.94M+44.8%	$28.27M+62.9%
Gain (loss) on sale of assets	-$50K—	——	——	——
Change in accounts receivable	——	$0—	$0—	——
Change in inventories	——	$0—	$0—	——
Change in accounts payable	——	$13.32M+7.8%	$12.36M—	——
Change in other assets	——	$5.97M—	——	——
Change in deferred revenue	——	$74K+105%	-$1.54M—	——
Non-cash operating lease expense	——	——	$1.21M—	——
Change in operating lease liabilities	——	——	-$546K—	——
Net cash from operating activities	-$377.92M-64.2%	-$230.19M-36.5%	-$168.6M-46.3%	-$115.21M-30.0%
Capital expenditures	$5.76M+49.9%	$3.84M-18.0%	$4.69M+183%	$1.66M+280%
Purchases of investments	$1B-12.4%	$1.15B+117%	$527.86M+60.0%	$329.82M+163%
Proceeds from maturities/sales of investments	$1.18B+106%	$575.8M+70.8%	$337.13M+114%	$157.49M+127%
Net cash from investing activities	$173.91M+129%	-$595.42M-197%	-$200.41M—	——
Proceeds from issuance of common stock	$0-100%	$781.39M+111%	$369.56M—	——
Net cash from financing activities	$40.61M-96.0%	$1.01B+159%	$391.24M+221%	$121.96M-51.7%
Effect of exchange rate changes on cash	——	$0—	$0—	——
Net increase (decrease) in cash	——	——	——	-$168.98M—
Accretion (Amortization) of Discounts and Premiums, Investments	$15.43M+3.3%	$14.93M+138%	$6.27M—	——
Operating lease liabilities	——	——	-$546K—	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	$5.97M—	——	——
Operating lease right-of-use asset amortization	——	——	$1.21M—	——
Proceeds From Sale And Maturity Of Available For Sale Securities	$1.18B+106%	$575.8M+70.8%	$337.13M+114%	$157.49M+127%
Payments Of Stock Issuance Costs	——	$14.98M+2,669%	$541K—	——
Proceeds from exercise of stock options and shares issued under Employee Stock Purchase Plan	$40.61M-9.0%	$44.61M+101%	$22.22M—	——
Amounts accrued for offering costs	——	——	——	——
Accrued payables for capital expenditures	——	——	$872K—	$0-100%
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	——	$0—	$0—	——
Increase Decrease In Operating Lease Liability	——	——	-$546K—	——
Stock options exercised receivable	——	——	——	——
Private company shares received under licensing arrangements	$0—	$0-100%	$2M—	——
Stock held in trust	——	——	$0—	——
Free cash flow	-$383.68M-63.9%	-$234.04M-35.1%	-$173.29M-48.3%	-$116.86M-31.3%
Free cash flow	-$383.68M-63.9%	-$234.04M-35.1%	-$173.29M-48.3%	-$116.86M-31.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Crinetics Pharmaceuticals's cash flow data come from?: Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.